A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction

Exclusion Criteria

• •1. Intention to treat subject with thrombolytic therapy following assertion of Thrombolysis In Myocardial Infarction(TIMI) flow 0 or 1 during qualifying angiogram
• •2. History of Myocardial infarctionI or congestive heart failure
• •3. Non-atherosclerotic etiology of acute myocardial infarction
• •4. Cardiogenic shock (systolic blood pressure \<90 despite adequate left ventricle filling pressure or requiring catecholamines) or other hemodynamic instability at baseline
• •5. Further transcatheter or surgical revascularization, e.g., coronary artery bypass graft planned per baseline angiogram
• •6. Lactating women
• •7. Past or present evidence of malignancy
• •8. Women who have had menarche but have not completed menopause, have not been surgically sterilized (bilateral tubal ligation or hysterectomy), do not have a partner with documented sterility (including vasectomy), or are not using adequate contraception (combined hormonal or double-barrier method of contraception, or sexual abstinence are the only methods of contraception acceptable for this study)
• •9. Ongoing infectious disease including human immunodeficiency virus (HIV) and hepatitis
• •10. Clinically significant respiratory, renal, metabolic, liver, central nervous system or other comorbid disease, except current cardiovascular disease